Translational Neurodegeneration
Translational Neurodegeneration (rendered in Chinese as 《转化神经变性病（英文）》 and commonly abbreviated as Transl. Neurodegener.) is an open access journal sponsored by Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine and co-published with BioMed Central. Launched in January 2012, it is devoted to translational research across neurodegenerative diseases, with a 2025 impact factor of 19.1.Translational Neurodegeneration（中文名《转化神经变性病（英文）》，常用缩写 Transl. Neurodegener.）是由上海交通大学医学院附属瑞金医院主办、与 BioMed Central 合作出版的开放获取期刊，2012 年 1 月创刊，专注神经变性病领域的转化研究，2025 年影响因子为 19.1。[1]
Scope
- Scope: the journal is an open access, peer-reviewed title covering research, therapeutics and education across all aspects of neurodegenerative diseases. It creates a novel interface between the fields of basic, translational and clinical research.学科定位： 期刊为开放获取、同行评审刊物，覆盖神经变性病的研究、治疗与教育各方面，在基础研究、转化研究与临床研究之间搭建新的交流界面。
- Subject coverage: it covers Parkinson's disease and movement disorders, Alzheimer's disease and other dementias, and motor neuron disease together with other neurodegenerative diseases. Specific interests include epidemiology and pathogenesis, diagnosis and prevention, research into disease pathogenesis, the development of new drugs and cell therapy, drug delivery, and rehabilitation.收录主题： 涵盖帕金森病与运动障碍、阿尔茨海默病与其他痴呆、运动神经元病及其他神经变性病，具体方向包括流行病学与发病机制、诊断与预防、疾病机制研究、新药与细胞治疗开发、药物递送以及康复。
- Distinctive position: organised around translation, the journal gives scientists, clinicians and physician-scientists a venue for their research and clinical trials that is applicable to their own specific field. It was the first English-language open access journal devoted to translational medicine in neurodegenerative diseases, in China and internationally.刊物特色： 以「转化」为主线，为科学家、临床医生与医师科学家提供发表研究与临床试验的平台，使成果可直接回用于各自的具体领域，是中国及国际上首本以神经变性病转化医学为定位的英文开放获取期刊。
- Article types and open access: all articles are published on a fully open access basis, so readers pay nothing and no subscription barrier stands before the author. The journal carries original research and review articles.体裁与开放获取： 全部文章以完全开放获取方式出版，读者无需付费即可阅读，稿件类型包含原创研究与综述。
- Indexing and metrics: the journal is indexed in the Science Citation Index Expanded, Medline, Scopus, DOAJ and PubMed Central, among others. It holds the first quartile in the JCR Neurosciences category and sits in the first division of the Chinese Academy of Sciences scheme for both medicine and neuroscience. The 2025 impact factor is 19.1, the five-year impact factor is 19.7, and the median time from submission to first decision is 11 days.收录与指标： 收录于科学引文索引扩展版、Medline、Scopus、DOAJ 与 PubMed Central 等数据库，在 JCR 神经科学类别中为第一区，属中科院医学与神经科学一区；2025 年影响因子为 19.1，五年影响因子为 19.7，稿件初审中位时间为 11 天。[2]
History
- Founded in 2012: the journal was launched in January 2012. Its first issue opened with a platform introduction by Shengdi Chen and Jialin C. Zheng.2012年创刊： 期刊于 2012 年 1 月创刊，创刊号首篇为陈生弟与郑加麟合撰的平台介绍文章。
- Background to the founding: research on neurodegenerative diseases had long lacked a dedicated meeting point between bench and bedside, and the journal was created to fill precisely that gap.创刊背景： 神经变性病研究长期在基础与临床之间缺乏专门的转化交流场所，该刊的创办正是为了填补这一空档。
- Founding editor: Professor Shengdi Chen founded the journal and served as its first editor-in-chief. He was then head of the Department of Neurology at Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine.创办人与首任主编： 陈生弟教授创办该刊并出任首任主编，其时任上海交通大学医学院附属瑞金医院神经内科主任。
- Publisher and partnership: the journal is sponsored by Ruijin Hospital and co-published with BioMed Central. The copyright line records joint ownership by Ruijin Hospital, Shanghai Jiao Tong University and BioMed Central Ltd., the last of these being part of Springer Nature.出版方与合作： 期刊由瑞金医院主办，与 BioMed Central 合作出版，版权页署明归瑞金医院、上海交通大学与 BioMed Central 有限公司共同所有，后者属 Springer Nature 体系。
- Milestones in indexing: the journal was accepted into the Science Citation Index Expanded in December 2017 and received its first impact factor in 2018. In the same year it obtained the Chinese national serial number CN 31-2159/R74, after which its international indexing coverage widened steadily.收录节点： 期刊于 2017 年 12 月被科学引文索引扩展版收录，2018 年获得首个影响因子，同年获国内统一连续出版物号 CN 31-2159/R74，此后国际检索覆盖逐步扩大。
- Recent metrics: the impact factor rose from about 5.5 in 2018 to above 10 in 2022, stood at 10.8 in 2023, and reached 19.1 in 2025.近年指标： 影响因子由 2018 年的约 5.5 升至 2022 年突破 10 分，2023 年为 10.8，2025 年达到 19.1。[3]
Editors
- Editor-in-chief: the journal is led by Professor Shengdi Chen of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine. His work centres on the clinical and translational study of Parkinson's disease and movement disorders.现任主编： 主编为陈生弟教授，任职于上海交通大学医学院附属瑞金医院，长期从事帕金森病与运动障碍的临床与转化研究。
- Editorial board: the board is international in composition and covers Parkinson's disease and movement disorders, Alzheimer's disease and other dementias, and motor neuron disease alongside other neurodegenerative diseases, mirroring the scope of the journal.编委构成： 编委为国际构成，方向覆盖帕金森病与运动障碍、阿尔茨海默病与其他痴呆、运动神经元病及其他神经变性病，与刊物的收稿范围相对应。
- Submission and peer review: manuscripts are lodged through the publisher's online submission system and undergo peer review. The editors publish a median submission-to-first-decision time of 11 days, the review being intended to be fast as well as thorough.投稿与评审： 稿件通过出版方的在线投稿系统递交，采用同行评审，编辑部公开初审中位时间为 11 天，评审以快速而详尽为目标。
- Institutional base: the editorial office draws on the clinical and academic resources of Ruijin Hospital and Shanghai Jiao Tong University, a connection the publisher lists among the journal's distinctive features.编务依托： 编辑部的工作依托瑞金医院与上海交通大学的临床与学术资源，这一依托也被出版方列为刊物的一项特色。
- Section editing: the board appoints section editors in three panels, devoted respectively to Alzheimer's disease and other neurodegenerative dementias, to Parkinson's disease and other movement disorders, and to other neurodegenerative diseases and neurogenetics.分栏编审： 编委会按疾病领域设专栏编辑，分为阿尔茨海默病与其他神经变性性痴呆、帕金森病与其他运动障碍、以及其他神经变性病与神经遗传学三组，分工负责相应方向的稿件。[4]